Embecta (EMBC) Scheduled to Post Quarterly Earnings on Thursday

Embecta (NASDAQ:EMBC) will issue its quarterly earnings data before the market opens on Thursday, May 9th. Analysts expect the company to announce earnings of $0.43 per share for the quarter. Embecta has set its FY 2024 guidance at 1.950-2.150 EPS.Individual interested in listening to the company’s earnings conference call can do so using this link.

Embecta (NASDAQ:EMBC) last announced its earnings results on Friday, February 9th. The company reported $0.61 EPS for the quarter, topping the consensus estimate of $0.46 by $0.15. The business had revenue of $277.30 million during the quarter, compared to the consensus estimate of $264.92 million. Embecta had a net margin of 4.93% and a negative return on equity of 18.66%. Embecta’s revenue was up .6% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.93 EPS. On average, analysts expect Embecta to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Embecta Stock Up 1.5 %

NASDAQ EMBC opened at $10.55 on Wednesday. The firm has a 50-day moving average price of $12.12 and a two-hundred day moving average price of $15.17. The company has a market capitalization of $607.46 million, a P/E ratio of 11.11 and a beta of 0.86. Embecta has a 12-month low of $9.93 and a 12-month high of $32.00.

Embecta Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, March 15th. Stockholders of record on Wednesday, February 28th were paid a $0.15 dividend. The ex-dividend date of this dividend was Tuesday, February 27th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 5.69%. Embecta’s payout ratio is currently 63.16%.

Insider Buying and Selling

In other Embecta news, Director David F. Melcher bought 2,000 shares of the stock in a transaction on Monday, February 12th. The stock was acquired at an average cost of $16.25 per share, for a total transaction of $32,500.00. Following the completion of the acquisition, the director now owns 45,080 shares in the company, valued at approximately $732,550. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. 0.28% of the stock is owned by corporate insiders.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.